Lipoprotein(a) – Medxy AI

Synergistic Risk Assessment: Coronary Artery Calcium Scoring Remains Vital in Patients with Elevated Lipoprotein(a)

By MedXY 03/30/2026

A large-scale multicohort study demonstrates that while elevated Lipoprotein(a) increases cardiovascular risk, Coronary Artery Calcium (CAC) scoring remains a powerful independent predictor of events, even in patients with high Lp(a) levels, providing essential clarity for clinical risk stratification.

Cardiology Internal Medicine news

Coronary Artery Calcium Scoring Remains the Definitive Risk Stratifier for Patients With Elevated Lipoprotein(a)

By MedXY 03/17/2026

A large multicohort study involving 11,319 participants confirms that Coronary Artery Calcium (CAC) scoring effectively stratifies cardiovascular risk even in individuals with high Lipoprotein(a), providing clinical clarity for personalized preventive strategies and the management of primary prevention patients.

Cardiology Neurology news

Lipoprotein(a) and the 30-Year Horizon: Redefining Long-Term Cardiovascular and Stroke Risk in Women

By MedXY 01/25/2026

Longitudinal data from the Women’s Health Study reveal that elevated Lipoprotein(a) is a potent, independent predictor of myocardial infarction and ischemic stroke over three decades, suggesting a critical need for universal screening in primary prevention to address long-term residual risk.

Cardiology news

Oxidized Phospholipids on ApoB-100: Dissecting the Link Between Lipoprotein(a), Platelet Reactivity, and Long-Term Cardiovascular Risk

By MedXY 12/30/2025

This evidence-based analysis of the EXCELSIOR trial explores the relationship between OxPL-apoB, platelet activation, and long-term outcomes, finding that while these phospholipids predict major cardiovascular events, they do not appear to mediate their risk through direct platelet reactivity pathways.

Cardiology Internal Medicine news

Alirocumab Neutralizes the Pro-inflammatory Risk of Oxidized Phospholipids After Acute Coronary Syndrome

By MedXY 12/25/2025

A secondary analysis of the ODYSSEY OUTCOMES trial reveals that oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) independently predict cardiovascular risk in ACS patients, particularly when Lp(a) levels are low. Treatment with alirocumab effectively mitigates this risk while significantly reducing biomarker levels.

Cardiology Clinical Updates news

Evaluating AHA PREVENT Equations and Lipoprotein(a) in Cardiovascular Risk Stratification: Integrative Insights from MESA and UK Biobank Cohorts

By MedXY 12/03/2025

This review synthesizes evidence on the performance of AHA PREVENT equations in individuals with elevated lipoprotein(a), emphasizing its independent risk association and potential to enhance personalized ASCVD risk prediction.

Cardiology news

High Lipoprotein(a) Predicts Recurrent ASCVD — Intensified LDL‑Lowering, Especially PCSK9 Inhibitors, May Attenuate Risk

By MedXY 12/02/2025

In 273,770 US patients with established ASCVD, rising lipoprotein(a) (nmol/L) was steadily associated with higher risk of recurrent events; the excess risk was partially blunted in those receiving high‑impact LDL‑lowering therapy, most notably PCSK9 inhibitors.

Cardiology Neurology news

Lipoprotein(a) and Dementia: Large Cohorts Show No Clear Link — But Small Apo(a) Isoforms May Raise Alzheimer’s Risk

By MedXY 11/28/2025

A pooled analysis of three large cohorts found no consistent association between circulating lipoprotein(a) and Alzheimer’s disease or vascular dementia, but genetic evidence for very small apo(a) isoforms suggests a modest increase in Alzheimer’s risk.

Cardiology Neurology Specialties

Long-Term Stroke Risk in Healthy Women: The Predictive Role of hsCRP, LDL Cholesterol, and Lipoprotein(a)

By MedXY 10/22/2025

A 30-year prospective study reveals that elevated hsCRP, LDL cholesterol, and lipoprotein(a) levels independently and collectively increase the risk of ischaemic stroke in healthy women, advocating for early biomarker screening in stroke prevention.

Cardiology Specialties

Lipoprotein(a) as a Prognostic Indicator for Extracoronary Atherosclerotic Disease Progression: Insights from the UK Biobank

By MedXY 09/06/2025

Elevated lipoprotein(a) levels significantly predict incident peripheral artery disease and carotid stenosis, as well as progression to major limb events, underscoring its value as a prognostic biomarker for extracoronary atherosclerotic vascular complications.

Cardiology Clinical Updates Medical News Neurology Specialties

Lipoprotein(a) as an Independent Predictor of Peripheral Artery Disease and Carotid Stenosis: Insights from a Large UK Biobank Study

By MedXY 08/01/2025

A landmark UK Biobank study demonstrates that elevated lipoprotein(a) independently predicts both the onset and progression of peripheral artery disease and carotid stenosis, beyond traditional cardiovascular risk factors.